Developing precision medicine for people of East Asian descent by unknown
REVIEW Open Access
Developing precision medicine for people
of East Asian descent
Stacy L. McAllister†, Katherine Sun† and Eric R. Gross*
Abstract
The goal of precision medicine is to separate patient populations into groups to ultimately provide customized care
tailored to patients. In terms of precision medicine, ~540 million people in the world have a genetic variant of the
aldehyde dehydrogenase 2 (ALDH2) enzyme causing a flushing response and tachycardia after alcohol consumption.
The genetic variant is identified as ALDH2*2 and originates from East Asian descendants of the Han Chinese. The variant
is particularly important to consider when discussing lifestyle choices with patients in terms of risk for developing
specific diseases, preventative screening, and selection of medications for treatment. Here we provide examples why
patients with an ALDH2*2 variant need more individualized medical management which is becoming a more standard
practice in the precision medicine era.
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Background
In 2015, the National Institutes of Health launched the
precision medicine initiative. This initiative describes
precision medicine as “an emerging approach for disease
prevention and treatment taking into account people’s
individual variations in genes, environment, and lifestyle”
with the ultimate goal of implementing these concepts
into clinical practice [1].
Some examples of precision medicine already exist in
medical practice. For example in pediatrics, a genetic
panel is typically used when a child is born, known as a
newborn screen, which in California tests for 57 differ-
ent conditions. If one of these genetic conditions is iden-
tified from the screen, individualized and rather specific
care is provided which can prevent serious health prob-
lems. Another example is recommendations for disease
surveillance based upon single gene variants which in-
crease the risk for colon cancer as seen in individuals
with Lynch syndrome or familial adenomatous polyposis.
These patients have established personalized guidelines
relevant to the frequency of medical surveillance for
colon cancer by colonoscopy which differs from colon
cancer screening measures recommended to the general
population [2].
Physicians are now also considering the influence of
genetic variants on drugs they prescribe when treating
specific conditions. For example, a variant in P450
CYP2C19 reduces the amount of the active form of clo-
pidogrel (a drug given when treating atrial fibrillation).
This is concerning since a subset of people with atrial
fibrillation and the CYP2C19 variant may not achieve a
therapeutic level of clopidogrel if prescribed the medica-
tion. Recently, physicians have started implementing
screening for the CYP2C19 variant as part of the med-
ical decision making process when determining which
drug to prescribe for atrial fibrillation [3].
Similar to the examples above, here we describe a gen-
etic variant which when factored in with environment and
lifestyle choices will influence medical management, pre-
ventative medicine, and drug treatment choices. This gen-
etic variant of the aldehyde dehydrogenase 2 (ALDH2)
enzyme is present in ~8 % of the world's population.
Here, we also briefly outline the initial steps for imple-
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Main text
Approximately 540 million people have a genetic variant
of the aldehyde dehydrogenase 2 (ALDH2) enzyme
which causes a flushing response and tachycardia after
alcohol consumption (Fig. 1). The genetic variant, identi-
fied as ALDH2*2, is almost exclusively present in East
Asian descendants of Han Chinese and is particularly
important when considering risk factors for disease, de-
cisions in medical treatment, and drug selection. Re-
cently, extensive reviews have covered the molecular
biology and importance of the ALDH2*2 variant in hu-
man health [4, 5]. Here, we concisely discuss 2 examples
of how the ALDH2*2 variant factors into decisions re-
garding medical management and drug selection. We
believe these two examples should be used as a founda-
tion for developing a more defined precision medicine
platform for those with an ALDH2*2 variant.
Developing precision medicine for ALDH2*2 in relation to
cancer risk
Undoubtedly, lifestyle choices contribute to the risk of
developing cancer. In particular, alcohol consumption
and cigarette smoking are two lifestyle choices which in-
crease the risk for esophageal cancer. Cigarettes contain
several reactive aldehydes (such as acrolein, formalde-
hyde and acetaldehyde) which are known carcinogens
[6]. The acetaldehyde produced from breaking down al-
cohol also is metabolized to acetaldehyde by the
ALDH2 enzyme.
In comparison to the United States, countries in Asia
have a higher incidence of esophageal cancer [7]. React-
ive aldehyde carcinogens are less efficiently metabolized
by those with an ALDH2*2 variant. With this in mind,
people with an ALDH2*2 variant are at a much greater
risk for esophageal cancer. A strong association be-
tween alcohol consumption and increased esophageal
cancer risk in the ALDH2*2 population has been
established [8, 9]. Alarmingly, people with an ALDH2*2
variant and also an alcohol dehydrogenase variant
(ADH1B, that causes a rapid conversion of alcohol to
acetaldehyde) with a history of drinking alcohol and
smoking cigarettes, have an odds ratio of 189 for devel-
oping esophageal cancer (Fig. 2) [10].
Taking this risk into consideration, similar to pub-
lished outlined measures for gastrointestinal cancers
with reference to specific genetic variants [2], in-
creased consideration should be given to developing
screening measures for esophageal cancer in the
ALDH2*2 population. This could potentially reduce
the incidence of esophageal cancer within the East
Asian population. Further, screening for the ALDH2*2
gene could be used as topic of conversation with pa-
tients as a preventative measure to reduce esophageal
cancer risk. These discussions could include how the
ALDH2*2 variant in combination with lifestyle choices
such as drinking alcohol or smoking cigarettes in-
creases the relative risk of developing esophageal can-
cer. Together, effectively communicating these lifestyle
risks can be a powerful means to reduce esophageal
cancer incidence.
Integrating the ALDH2*2 variant into medical decisions
when prescribing drugs
Besides the importance for ALDH2 in metabolizing
acetaldehyde (the breakdown product of alcohol),
ALDH2 is also an important enzyme in drug metabol-
ism. The efficacy of several drugs are impacted by the
ALDH2*2 variant [4]. Specifically, ALDH2 metabolizes
nitroglycerin to nitric oxide in order to cause blood
vessel dilation. Importantly, those with an ALDH2*2
variant are less efficient at breaking down nitroglycerin
to nitric oxide, effectively limiting the vasodilatory ef-
fect of nitroglycerin. The catalytic activity to metabolize
nitroglycerin is 10-fold less for the ALDH2*2 enzyme
Fig. 1 The genetic variant ALDH2*2. The ALDH2*2 variant is present in 540 million people in the world mainly of Han Chinese descent. The
variant is identifiable by the phenotypic response of facial flushing after alcohol consumption. People heterozygotic for the genetic variant
(ALDH2 *1*2) have at least a 60 % decrease in enzymatic activity while those homozygotic (ALDH2 *2*2) have greater than a 95 % decrease in
enzymatic activity
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compared to the ALDH2*1 enzyme [11]. Studies in East
Asians, measuring forearm blood flow response to
nitroglycerin show that ALDH2*2 variants have a 40 %
reduced response compared to those without a *2 vari-
ant as measured by vasodilation (Fig. 3) [12].
Importantly, the influence of ALDH2*2 on nitrogly-
cerin metabolism may impact medical decision making
in several medical disciplines including anesthesiology,
obstetrics, cardiology, internal medicine, and emergency
medicine. Nitroglycerin is commonly given after cardiac
bypass for a heart valve replacement or coronary artery
bypass grafting. Nitroglycerin is also used in obstetrics
to relax the uterus. In cardiology and emergency medi-
cine, nitroglycerin is frequently given to relieve chest
pain associated with myocardial ischemia. Many of these
nitroglycerin applications in medical practice may need
to consider potential ALDH2*2 variant effects on nitro-
glycerin efficacy. With knowledge of this genetic infor-
mation, clinicians can consider either increasing the
nitroglycerin dose given or choosing another vasodilator
which is not metabolized by the ALDH2 enzyme, such
as nitroprusside.
Conclusions
With a focus on precision medicine and the high preva-
lence of the ALDH2*2 variant within the East Asian
population, clinicians should consider whether a patient
has this variant which increases the risk for specific dis-
eases such as esophageal cancer and limits the metabol-
ism of specific drugs such as nitroglycerin. One option
to consider is more frequent screening for esophageal
cancer for those with both the ALDH2*2 variant and a
history of smoking cigarettes and/or consuming alcohol.
When the potential influence of the ALDH2*2 variant is
taken into consideration, relative to disease risk and
drug metabolism, patients with the ALDH2*2 variant
can begin receiving personalized medical management
which will become standard practice in the precision
medicine era.
Fig. 3 Reduced metabolism of nitroglycerin to nitric oxide. The esterase activity for the ALDH2 enzyme is required to convert nitroglycerin to
nitric oxide. Those with the ALDH2*2 variant also have a reduction in esterase activity, which in turn causes nitroglycerin to be less efficiently
metabolized to nitric oxide. Approximately 40 % more nitroglycerin may need to be given to people with the ALDH2*2 variant to achieve the
same effect as those with the ALDH2*1 enzyme
Fig. 2 The influence of genetics and lifestyle choices on esophageal cancer risk. People with the ALDH2*2 variant who consume alcohol and are
also fast metabolizers of alcohol by having the ADH1B variant have an increased risk for developing esophageal cancer. If the person also smokes
cigarettes, the risk of developing esophageal cancer is potentially 189 times higher
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